Silo Pharma, Inc. (SILO) — Financial statements
Income statement, balance sheet, and cash flow for Silo Pharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.07↑0.0% | 0.07↑0.0% | 0.07↑0.0% | 0.07↑1.2% | 0.07 | |
| Cost of Revenue | 0.89↑15077.4% | 0.01↑0.0% | 0.01↑0.0% | 0.01↑16.7% | 0.01 | |
| Gross Profit | -0.81↓1328.4% | 0.07↑0.0% | 0.07↑0.0% | 0.07↑0.0% | 0.07 | |
| Operating Expenses | ||||||
| R&D Expenses | 2↓8.8% | 2↑180.2% | 0.85↓34.3% | 1↑85.4% | 0.69 | |
| General & Administrative Expenses | 2↓10.7% | 2↓21.9% | 3↑26.7% | 2↑7.2% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 2↓10.7% | 2↓21.9% | 3↑26.7% | 2↑7.2% | 2 | |
| Other Expenses | -0.84 | 0.00 | 0.00↑100.0% | -0.02↑86.5% | -0.15 | |
| Operating Expenses | 3↓27.4% | 5↑21.7% | 4↑6.2% | 4↑31.4% | 3 | |
| Total Costs & Expenses | 4↓8.9% | 5↑21.6% | 4↑6.2% | 4↑31.4% | 3 | |
| Operating Results | ||||||
| Operating Income | -4↑9.0% | -5↓22.0% | -4↓6.3% | -4↓32.2% | -3 | |
| Depreciation & Amortization | 0.01↑85.0% | 0.01 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -4↑2.3% | -4↓20.8% | -4↑7.1% | -4↓193.3% | 4 | |
| EBIT | -4↑2.4% | -4↓21.0% | -4↑7.1% | -4↓193.3% | 4 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.16↓52.3% | 0.33↓16.7% | 0.39↑458.9% | 0.07↑3957.5% | -0.00 | |
| Interest Income | 0.19↓41.8% | 0.33↓16.4% | 0.40↑448.7% | 0.07↑5903.1% | 0.00 | |
| Interest Expense | 0.04↑633.7% | 0.01↑4.4% | 0.00↑121.4% | 0.00↓27.6% | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.32↓38.6% | -0.23↓182.6% | 0.28↑104.0% | -7 | |
| Other Income / Expenses | 0.05↓83.1% | 0.31↑39.3% | 0.22↑180.3% | -0.28↓104.0% | 7 | |
| Income Before Tax | -4↑3.8% | -4↓21.0% | -4↑7.1% | -4↓193.4% | 4 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -4↑3.8% | -4↓21.0% | -4↑7.1% | -4↓194.0% | 4 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↑100.0% | -0.07↓5884.5% | -0.00↑99.5% | -0.25 | |
| Net Income | -4↑3.8% | -4↓18.7% | -4↑5.3% | -4↓200.1% | 4 | |
| Bottom-Line Net Income | -4↑3.8% | -4↓18.7% | -4↑5.3% | -4↓256.4% | 2 | |
| EPS (Basic) | -0.50↑58.0% | -1.19↑0.8% | -1.20↑29.8% | -1.71↓229.5% | 1.32 | |
| EPS (Diluted) | -0.50↑58.0% | -1.19↑0.8% | -1.20↑29.8% | -1.71↓231.5% | 1.30 | |
| Weighted Average Shares | 8↑127.8% | 4↑19.5% | 3↑34.8% | 2↑20.4% | 2 | |
| Weighted Average Diluted Shares | 8↑127.8% | 4↑19.5% | 3↑34.8% | 2↑19.1% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.